surface antigen (HBsAg) but also in patients with "resolved" HBV infection. 5,6 In a retrospective analysis of lymphoma patients who were HBsAg-negative and anti-HBV core antigen (anti-HBc) positive, 5 of the 21 patients who received chemotherapy plus rituximab, an anti-CD20 antibody, developed hepa
Incidence of hepatocellular carcinoma in hepatitis C carriers with normal alanine aminotransferase levels
β Scribed by Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Hiroyuki Atsumi; Makiko Takagi; Satoshi Nakano; Takahiro Arakawa; Masashi Fujimori
- Book ID
- 116651794
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 238 KB
- Volume
- 50
- Category
- Article
- ISSN
- 0168-8278
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The importance of alanine aminotransferase (ALT) levels in the progression of hepatitis B virus (HBV) infection remains a subject of debate. This study sought to identify independent risk factors involved in development of hepatocellular carcinoma (HCC), particularly in patients with ch
Chronic hepatitis B patients with high-normal serum ALT (levels of 0.5-1Ψ upper limit of normal) are still at risk of liver disease progression. We thus investigated the correlation between serum ALT level and hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum ALT le